Objective To analyze the prevalence of HIV-1 genotypes and the transmitted drug resistance in HIV/AIDS patients before antiviral treatment from 2020 to 2023 in Nanning City,provide a reference for the development of prevention and control strategies for newly reported HIV infections in the region.Method 374 whole blood specimens from newly confirmed non-ART HIV/AIDS patients in Guangxi from January 2020 to December 2023 were collected for HIV-1 drug resistance testing.After extracted nucleic acids were reverse transcribed,the HIV-1 pol region gene was amplified by nested PCR and sequenced by Sanger sequencing,and the sequence information was analyzed according to tools such as the Stanford University HIVdb Program Drug Resistance Database.Result A total of 346 samples were successfully sequenced.Among them 9 subtypes were detected,mainly CRF01_AE subtypes and B/C recombinant,accounting for 29.48％and 27.46％.The subtype distribution between males and females was significantly different,and the subtype distribution in different sex-transmitted infections was also significantly different(P＜0.05).The overall drug resistance rates of PDR was 8.09％(28/346)with 2.89％to NRTIs,3.75％to NNRTIs,1.73％to PIs,and 0.29％to INSTIs.The drug resistance mutation rate of genotypic subtypes was 22.83％(79/346),and the mutation rates of resistance sites for NRTIs,NNRTIs,PIs and INSTIs were 4.91％,15.32％,2.02％and 2.31％,respectively.Conclusion Newly reported patients with HIV infection/AIDS in Nanning City are mainly CRF01-AE subtype HIV-1 infections,meanwhile,the pre-ART resistance rate has reached a medium-high level,and INSTIs resistant strains have emerged.Surveillance of HIV-1 subtypes prevalence and the drug resistance monitoring of newly reported HIV-infected people before ART need to be strengthened.
关键词
艾滋病/抗病毒治疗前耐药/HIV-1亚型/耐药突变
Key words
Human immunodeficiency virus/Drug resistance before treatment/HIV-1 subtype/Drug resistance mutation
维普
万方数据